Shanghai Hengrui Pharmaceutical Co., Ltd.
- Trials
- 0
- Subs
- 0
- People
- 0
- Links
- 0
Executive Summary
AI synthesisShanghai Hengrui Pharmaceutical Co., Ltd. appears to be a subsidiary or affiliate of Jiangsu Hengrui Medicine Co., Ltd. (SHA:600276), one of China's largest pharmaceutical companies with a strong oncology and innovative drug pipeline. The company maintains clear BIOSECURE status, making it an attractive partner for US BD teams. However, limited public information on this specific subsidiary suggests it may be a smaller operating unit focused on regional Shanghai operations or specific therapeutic areas.
Structure: This entity appears to be a regional subsidiary of the publicly-traded Jiangsu Hengrui Medicine Co., Ltd., likely structured as a WOFE (wholly foreign-owned enterprise) or domestic subsidiary for Shanghai market operations. The lack of detailed subsidiary information suggests this may be a smaller operating unit rather than a major holding company structure.
BIOSECURE Risk
Clear BIOSECURE status with no BCC designation, and likely connection to established Hengrui group which has maintained good standing with US regulators
Key Exposures:
- •Potential future policy changes affecting Chinese pharmaceutical companies
- •Parent company regulatory status changes
Mitigation: Clear status maintained, but limited visibility into specific compliance measures for this subsidiary
BD Intelligence
Therapeutic Areas:
Recent Deals: No recent deal activity recorded for this specific entity
Approach: Approach through parent company Jiangsu Hengrui channels, as this subsidiary may have limited independent BD authority
Red Flags
- ⚠Limited public disclosure and transparency
- ⚠Unclear operational scope and independence from parent company
- ⚠No visible pipeline or recent corporate activity
- ⚠Potential dormant or inactive subsidiary status
Quick Facts
- Key People
- 0
- Subsidiaries
- 0
- CDMO/CRO Subs
- 0
- Genomics Subs
- 0
- Direct BIOSECURE
- 0
- Corp Events
- 0
- Gov-Connected
- 0
- Clinical Trials
- 0
- Publications
- 0
- Drug Molecules
- 0
- Relationships
- 0
Sources & Methodology
Clinical trials data: ClinicalTrials.gov API v2 (0 trials linked to this entity)
SEC BIOSECURE filings: EDGAR EFTS full-text search (850+ filings from 230 companies)
Publications: Europe PMC API (0 publications indexed)
Drug molecules: ChEMBL database (European Bioinformatics Institute)
Financial data: East Money (东方财富) datacenter API / CNINFO (巨潮资讯网)
Corporate structure: Company official filings, HKEX/SSE/SZSE disclosures
Executive profiles: Company official biographies, SEC filings, LinkedIn (where verified)
Data is collected from public sources and updated weekly. Corporate intelligence is verified by a native Mandarin-speaking analyst against Chinese-language primary sources including Tianyancha (天眼查), GSXT (国家企业信用信息公示系统), and CNINFO (巨潮资讯网). This is not financial or legal advice.